Analysis of referral to first treatment pathways by Cancer Alliance using 2017/18 cancer waiting times (CWT) data for colorectal, lung and prostate cancers

Lucy Young
Senior Cancer Analyst, CADEAS
February 2019
Brief introduction to CADEAS and Cancer Alliances

• The Cancer Alliance Data, Evidence and Analysis Service (CADEAS) is a partnership between NHS England and Public Health England

• CADEAS was established in 2017/18 to support the Cancer Alliances’ analytical needs enabling them to lead transformation using a whole pathway and cross-organisational approach

• 19 Cancer Alliances to deliver the Cancer Programme across the country to transform services for patients
BACKGROUND: Analysis of referrals to first treatment pathways using 2017/18 Cancer Waiting Times data for Colorectal, Lung and Prostate Cancers
Purpose of Work

**Aims:** to provide Cancer Alliances with analysis of pathways with a 62-day Cancer Waiting Times (CWT) record for colorectal, lung and prostate cancers. This is to enable Cancer Alliances to support:

- implementation of the best practice timed pathways; and
- meeting 62-day CWT operational standards.

- The work is also aimed at helping Cancer Alliances understand where variations are occurring within the Cancer Alliances and cancer types, and to identify where best practice can be shared.
Methodology

- This analysis uses 2017/18 CWT dataset records for colorectal (C18-20), lung (C34) and prostate (C61) cancers on a 62-day CWT pathway. A total of 47948 patients were included in the analysis.

- Patients registered to Welsh commissioners or private trusts were excluded from the analysis.

- This analysis is segmented by:
  - Cancer type
  - Cancer Alliance
  - Days from referral to first treatment
  - First treatment modality received
  - Days from referral to first treatment by first treatment modality received
RESULTS: Analysis of referrals to first treatment pathways using 2017/18 Cancer Waiting Times data for Colorectal, Lung and Prostate Cancers
Colorectal cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Colorectal cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Lung cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Lung cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Prostate cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Prostate cancer: variation in days from a CWT referral to first treatment received, by Cancer Alliance (2017/18, 62-day referrals)
Colorectal cancer: variation in days from a referral to first treatment received, by the five most common treatment modalities (2017/18)

Patients receiving treatment modality

<table>
<thead>
<tr>
<th>Treatment Modality</th>
<th>Proportion of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemoradiotherapy</td>
<td>7.2%</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>9.3%</td>
</tr>
<tr>
<td>Palliative care only</td>
<td>9.7%</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>5.2%</td>
</tr>
<tr>
<td>Surgery</td>
<td>68.8%</td>
</tr>
</tbody>
</table>

CWT interval (days)
- 100+ days
- 63-99 days
- 53-62 days
- 32-52 days
- 0-31 days
Lung cancer: variation in days from a referral to first treatment received, by the five most common treatment modalities (2017/18)

<table>
<thead>
<tr>
<th>Treatment Modality</th>
<th>Patients receiving treatment modality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7.5%</td>
</tr>
<tr>
<td></td>
<td>31.9%</td>
</tr>
<tr>
<td></td>
<td>22.4%</td>
</tr>
<tr>
<td></td>
<td>14.4%</td>
</tr>
<tr>
<td></td>
<td>23.8%</td>
</tr>
</tbody>
</table>

Proportion of patients

- Active monitoring: 41%
- Chemotherapy: 55%
- Palliative care only: 33%
- Radiotherapy: 62%
- Surgery: 61%
Prostate cancer: variation in days from a referral to first treatment received, by the five most common treatment modalities (2017/18)

Patients receiving treatment modality

- Active monitoring: 27.0%
- Brachytherapy: 0.8%
- Hormonal therapy: 57.7%
- Radiotherapy: 0.6%
- Surgery: 13.9%

CWT interval (days):
- Orange: 100+
- Yellow: 63-99
- Blue: 53-62
- Light blue: 32-52
- Lightest blue: 0-31
Summary

• There is lots of variation occurring in the time taken from referral to treatment by Cancer Alliance and within Cancer Alliances by cancer type and first treatment modality received.

• Cancer Alliances are encouraged to use the reports to identify where variation is occurring and where best practice can be shared.

• The national and CCG reports can be found here: http://www.ncin.org.uk/local_cancer_intelligence/cadeas

• Limitation: this work only analyses those on a 62-day pathway diagnosed with colorectal, lung or prostate cancer with a 2017/18 CWT record. This prevents linking to patient demographics including stage to understand the variation in more detail.
Acknowledgements

• This work uses data provided by patients and collected by the NHS as part of their care and support.

• Lead analyst: Dr Joanna Pethick

• Others working on this project: Amy Lee, Fazaan Dasu, Joe Alderson

• This work is produced by the Cancer Alliance Data, Evidence and Analysis Service (CADEAS), a partnership between NHS England and Public Health England. It builds on work previously carried out by RM Partners for the three Cancer Vanguard sites.

• All feedback welcome (lucy.young14@nhs.net)